Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
Martin G. Sanda(Emory University), James E. Montie(University of Michigan), Diane E. Milenic(National Institutes of Health), Dennis Panicali(Fox Chase Cancer Center), Kenneth J. Pienta(Johns Hopkins University), Jeff Schlom(Universal-Kugellager-Fabrik (Germany)), Linda G. Charles(University of Michigan), David C. Smith(University of Michigan), Clara Hwang(Henry Ford Health System)
Cited by 204
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k